Skip to main content

Microbiome-Based Deal Benchmarks in Metabolic & Obesity

Median Upfront
$533M
Range: $292M - $764M
Total Deal Value
$2.5B
Range: $1.6B - $3.4B
Royalty Rate
13.5% - 24.8%
Tiered up to 28.8%
Dev Milestones
$359M
Range: $243M - $476M
Model Your Deal

Market Analysis

Microbiome-Based therapies in metabolic & obesity have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 microbiome-based asset in metabolic & obesity is $533M, with total deal values reaching $2.5B. Development milestones average $359M, while regulatory milestones contribute $438M.

The metabolic & obesity microbiome-based landscape is characterized by extremely high competitive intensity driven by the GLP-1 revolution and massive obesity market opportunity. Oral formulations, dual/triple incretins, and muscle-sparing approaches command unprecedented deal valuations. The recommended deal structure allocates approximately 21% to upfront payments and 79% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for microbiome-based metabolic & obesity deals range from 13.5% to 24.8% at the base tier, with tiered escalation reaching 17.5%-28.8% on blockbuster sales. Commercial milestones averaging $1.2B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a microbiome-based metabolic & obesity licensing deal?
Based on our analysis, Phase 2 microbiome-based licensing deals in metabolic & obesity average $533M in upfront payments, with a range of $292M to $764M depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for microbiome-based metabolic & obesity transactions?
The median total deal value for Phase 2 microbiome-based assets in metabolic & obesity is $2.5B, ranging from $1.6B to $3.4B. This includes development milestones ($359M), regulatory milestones ($438M), and commercial milestones ($1.2B).
What royalty rates are standard for microbiome-based deals in metabolic & obesity?
Base royalty rates for microbiome-based metabolic & obesity transactions range from 13.5% to 24.8%, with tiered escalations reaching 17.5%-28.8% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in microbiome-based metabolic & obesity deals?
Microbiome-Based metabolic & obesity deals allocate approximately 79% of total deal value to milestones. Development milestones ($359M) make up the largest share, followed by commercial milestones ($1.2B) and regulatory milestones ($438M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Metabolic & Obesity

View

GLP-1 Agonist in Metabolic & Obesity

View

Microbiome-Based in Gastroenterology

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included